Kangtai Bio
Kangtai Bio
Kangtai Bio a famous international pharmaceutical company
Kangtai Bio is one of the first high-tech enterprises in Shenzhen, mainly engaged in the development, production and sales of biological products. It has a team of vaccine industry professionals who have made important breakthroughs in the research and development of new vaccines. The production line is imported from Merck, a famous international pharmaceutical company, and its safety and efficacy have been guaranteed, and the products have covered 31 provinces, municipalities and autonomous regions.
- All
- News
- Analysis
- Research
Briefing Mar 24, 2021 05:40 PM
· Healthcare
Cancer cell therapy company raised CNY 500 million in D round
Briefing Mar 01, 2021 11:55 AM
· Healthcare
Baiji Shenzhou PD-1 inhibitor price dropped by 80%
In depth
Healthcare
Bid for Molecular Tech in China's Early-Stage Cancer Detection Market
China, with a population of 1.4 billion, has one of the largest gene pools in the world. How does its DNA tech-based cancer detection industry look? Listed on Nasdaq in 2020, Genetron Holdings Limited (Genetron Health) is taking a leading role.
Sep 09, 2020 03:08 PM
Briefing Feb 07, 2021 06:55 PM
· Healthcare
Deyi sunshine completed tens of millions of Yuan round B financing
Briefing Feb 05, 2021 02:07 PM
· Healthcare
Novozyme plus R-CHOP Regimen for first-line treatment of mantle cell lymphoma
Research
Healthcare, Technology, Consumer StaplesWIA2020 | Rising Tech Stars 2020: Global & China's 100
Dec 09, 2020 09:57 AM
Dec 09, 2020 09:39 AM
Dec 09, 2020 08:55 AM
Research
Consumer Staples, Real Estate, Consumer DiscretionaryTech for Global, Globalization Footprints of the Established and the New
May 29, 2020 08:30 PM
Briefing Feb 03, 2021 09:42 AM
· Healthcare
Jingtai technology has signed cooperation with new Geyuan to develop targeted drugs with AI and single cell sequencing as new tumor targets
Briefing Feb 01, 2021 02:41 PM
· Healthcare
Bh009 new drug project independently researched and developed by Beihai biological Co., Ltd. was approved by China's clinical trials
Briefing Jan 08, 2021 11:30 AM
· Healthcare
Xinyi biological completed 150 million round B financing, and Lilly Asia Fund led investment in Huachuang capital, hillhood venture capital and other follow-up investment
Briefing Jan 08, 2021 09:36 AM
· Healthcare
Focus on high-throughput single-cell omics platform products, search for a reason to complete more than 100 million yuan round a financing
Healthcare
Revenue and Net Profit of Wuxi Apptec Both Increased in 2020
Wuxi apptec said that the main reasons for the company's performance growth were the high growth of laboratories in China and the year-on-year growth of CDMO plate. China laboratory service is the core business of Wuxi apptec, accounting for more than 50% of its revenue. Its main business is small molecule drug discovery, drug analysis and testing.
Apr 01, 2021 04:39 PM
Briefing Jan 07, 2021 04:13 PM
· Healthcare
Qiuzhen medical and tianguangshi have reached strategic cooperation to develop diagnostic kits and tumor drugs
Briefing Dec 31, 2020 10:20 AM
· Healthcare
Sinopharm new coronavirus vaccine approved
Briefing Dec 30, 2020 05:28 PM
· Healthcare
Another protein component special medical food was approved, and the total number of approved products increased to 57
Healthcare
WIM2020: Insights on the Post-pandemic Outlook for the Healthcare Industry
The curtain came down on Dec 10 on the 'Healthtech Industry and COVID-19 Pandemic' Chapter at WIM 2020. Healthtech entrepreneurs and investors gathered to share insights on the outlook for the healthcare industry, covering topics like vaccination, AI healthcare, intelligent hardware, medical appliances and IVD.
Jan 07, 2021 02:10 PM
Briefing Dec 28, 2020 03:13 PM
· Healthcare
Phase I project of Guangzhou Pharmaceutical production base of nuocheng Jianhua was completed
Briefing Dec 28, 2020 02:44 PM
· Healthcare
BGI and Hanwei intelligent medical jointly launched mobile "two cancer" intelligent screening
Briefing Dec 23, 2020 11:21 AM
· Healthcare
Asc41, a candidate drug for NASH, was administered to overweight and obese subjects in phase IB clinical trial
Briefing Dec 20, 2020 02:22 PM
· Healthcare
Fosun medicine: the new crown vaccine has been included in the domestic phase II clinical, and no serious adverse report has been received
See more
Related Companies
EqualOcean Analysis
- Black Swans and Breakthroughs: China's Top 50 Innovative Public Firms in 2020
- China Speed: Two COVID-19 Vaccines Recognized by WHO
- After China's BNR and GTH Hit Nasdaq, Pan-Cancer Detector GRAIL Eyes IPO
- More Room for the Medical Device Market to Grow in China
- Tong Ren Tang: Any Hope for this Purveyor of Centuries-Old Chinese Medicines?
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.